The management of the MS Center Amsterdam will change as of April, 2021

In addition to general director professor Bernard Uitdehaag, professor Elga de Vries will join the newly established executive board as scientific director. Besides the two directors senior researchers from seven different departments where MS research is performed will form the general board of the MS Center Amsterdam.

 

Managing board

Professor Bernard Uitdehaag, neurologist and chair of the department of Neurology at Amsterdam UMC, has been director of MS Center Amsterdam since 2013. From April 1, he will be joined for the daily management by professor Elga de Vries. She has been at Amsterdam UMC since 2000 as a neuro-immunological researcher in the department of Molecular Cell Biology and Immunology. Her research group Neuro-immunology focuses on unraveling disease mechanisms of MS at a cellular level in order to find new targets for treatments.

 

General Board

The general board consists of eight senior researchers from seven departments within Amsterdam UMC. Their task is to jointly provide the vision and mission of the MS Center Amsterdam and a draw a strategy to achieve set goals.

 

Members general board

·         prof. dr. Jeroen Geurts, Anatomy and Neuroscience

·         prof. dr. Vincent de Groot, Rehabilitation medicine

·         prof. dr. Joep Killestein, Neurology

·         prof. dr. Charlotte Teunissen, Clinical chemistry

·         prof. dr. Bernard Uitdehaag, Neurology

·         prof. dr. Paul van der Valk, Pathology

·         dr. ir. Hugo Vrenken, Radiology and nuclear medicine

·         prof. dr. Elga de Vries, Molecular Cell Biology and Immunology

 

MS Center Amsterdam Office

The managing and general board will be supported by the MS Center Amsterdam Office.

·         dr. Annette van der Goes

·         Karin Husken

 

Ernesto Rodriguez Camejo – publication in Nature Communications: Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most severe cancer types with a

5-year survival of 9% . The PDAC TME is characterized by dense fibrotic stroma
and suppressive immune cells that repress anti-tumor immune responses and
contribute to cancer progression. In this paper, Rodriguez et al showed that
pancreatic tumor cells present an increased expression of a particular glycan
structure, sialic acid, capable to shape immune responses by inducing
tolerogenic programs in myeloid cells. This work highlights a critical role for
sialylated glycans in controlling immune suppression and provides new potential
targets for cancer immunotherapy in PDAC.

Retinoic Acid in Immune Homeostasis

Martje Erkelens

Retinoic Acid in Immune Homeostasis

Thesis defense: 23-9-2020

Promotor: prof. dr. R. Mebius. Copromotor: prof. dr. M. van Egmond

Thesis defense: 1-7-2021